PDCD1 and neoplasm: Clinical PET imaging with [89Zr]-DFO-pembrolizumab in patients with NSCLC was able to detect tumor lesions and, notably, response to anti-PD-1 treatment could be correlated with higher [89Zr]Zr-DFO-pembrolizumab uptake (42, 99).